259 related articles for article (PubMed ID: 28270509)
1.
Li K; Cheng X; Tilevik A; Davis SJ; Zhu C
J Biol Chem; 2017 Apr; 292(16):6799-6809. PubMed ID: 28270509
[TBL] [Abstract][Full Text] [Related]
2. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
3. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
4. Structure and interactions of the human programmed cell death 1 receptor.
Cheng X; Veverka V; Radhakrishnan A; Waters LC; Muskett FW; Morgan SH; Huo J; Yu C; Evans EJ; Leslie AJ; Griffiths M; Stubberfield C; Griffin R; Henry AJ; Jansson A; Ladbury JE; Ikemizu S; Carr MD; Davis SJ
J Biol Chem; 2013 Apr; 288(17):11771-85. PubMed ID: 23417675
[TBL] [Abstract][Full Text] [Related]
5. Differential binding properties of B7-H1 and B7-DC to programmed death-1.
Youngnak P; Kozono Y; Kozono H; Iwai H; Otsuki N; Jin H; Omura K; Yagita H; Pardoll DM; Chen L; Azuma M
Biochem Biophys Res Commun; 2003 Aug; 307(3):672-7. PubMed ID: 12893276
[TBL] [Abstract][Full Text] [Related]
6. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
Su Z; Dhusia K; Wu Y
PLoS Comput Biol; 2021 Mar; 17(3):e1008825. PubMed ID: 33684103
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
Ishida M; Iwai Y; Tanaka Y; Okazaki T; Freeman GJ; Minato N; Honjo T
Immunol Lett; 2002 Oct; 84(1):57-62. PubMed ID: 12161284
[TBL] [Abstract][Full Text] [Related]
8. PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.
Peña-Cruz V; McDonough SM; Diaz-Griffero F; Crum CP; Carrasco RD; Freeman GJ
J Invest Dermatol; 2010 Sep; 130(9):2222-30. PubMed ID: 20445553
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 Binds to B7-1 Only
Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
[TBL] [Abstract][Full Text] [Related]
10. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Butte MJ; Keir ME; Phamduy TB; Sharpe AH; Freeman GJ
Immunity; 2007 Jul; 27(1):111-22. PubMed ID: 17629517
[TBL] [Abstract][Full Text] [Related]
11. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
Keir ME; Latchman YE; Freeman GJ; Sharpe AH
J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
[TBL] [Abstract][Full Text] [Related]
12. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
13. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
14. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
Freeman GJ; Long AJ; Iwai Y; Bourque K; Chernova T; Nishimura H; Fitz LJ; Malenkovich N; Okazaki T; Byrne MC; Horton HF; Fouser L; Carter L; Ling V; Bowman MR; Carreno BM; Collins M; Wood CR; Honjo T
J Exp Med; 2000 Oct; 192(7):1027-34. PubMed ID: 11015443
[TBL] [Abstract][Full Text] [Related]
15. Interaction of human PD-L1 and B7-1.
Butte MJ; Peña-Cruz V; Kim MJ; Freeman GJ; Sharpe AH
Mol Immunol; 2008 Aug; 45(13):3567-72. PubMed ID: 18585785
[TBL] [Abstract][Full Text] [Related]
16. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
17. Fine-tuned expression of programmed death 1 ligands in mature dendritic cells stimulated by CD40 ligand is critical for the induction of an efficient tumor specific immune response.
Gu T; Zhu YB; Chen C; Li M; Chen YJ; Yu GH; Ge Y; Zhou SY; Zhou H; Huang Y; Qiu YH; Zhang XG
Cell Mol Immunol; 2008 Feb; 5(1):33-9. PubMed ID: 18318992
[TBL] [Abstract][Full Text] [Related]
18. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.
Kanai T; Totsuka T; Uraushihara K; Makita S; Nakamura T; Koganei K; Fukushima T; Akiba H; Yagita H; Okumura K; Machida U; Iwai H; Azuma M; Chen L; Watanabe M
J Immunol; 2003 Oct; 171(8):4156-63. PubMed ID: 14530338
[TBL] [Abstract][Full Text] [Related]
19. The CTLA-4 immune checkpoint protein regulates PD-L1:PD-1 interaction via transendocytosis of its ligand CD80.
Kennedy A; Robinson MA; Hinze C; Waters E; Williams C; Halliday N; Dovedi S; Sansom DM
EMBO J; 2023 Mar; 42(5):e111556. PubMed ID: 36727298
[TBL] [Abstract][Full Text] [Related]
20. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
Zhu B; Guleria I; Khosroshahi A; Chitnis T; Imitola J; Azuma M; Yagita H; Sayegh MH; Khoury SJ
J Immunol; 2006 Mar; 176(6):3480-9. PubMed ID: 16517716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
